Physicians' Academy for Cardiovascular Education

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt

Video navigation menu

  • Undertreatment of CV risk factors is seen globally 0:09
  • Ongoing CV outcomes trials of PCSK9 inhibitors as secondary prevention 1:21
  • CV risk reduction in diabetes 3:07
  • Long-term double antiplatelet therapy as secondary CV prevention 3:59
  • Integrating PCSK9 inhibiting therapy into primary and secondary prevention 7:57
  • How to combine anti-PCSK9 treatment with other preventive strategies? 8:53

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: